Wednesday, April 21, 2021
Home Clinical Data Management ECOG Performance Status

ECOG Performance Status

ECOG Performance Status-scale was developed by Eastern Cooperative Oncology Group. Now this group is a part of ECOG-ACRIN Cancer Research Group.
This scale was published in 1982.

Importance of ECOG performance status:

  • It provides standard criteria to measure the impact of disease on patient’s daily living abilities/performances for example, ability to walk, Office work etc.
  • It helps sponsor to recruit Desired population in oncology studies.
  • It also provides considerable information about treatment effect on patient’s level of functioning.
  • Data Manager can get the information about this while reviewing the protocol in oncology trials as all protocol clearly mentions which performance Grading system needs to be used. (other performance Grading System: Karnofsky Performance Status)
  • Please refer the below table which is taken from ECOG-ACRIN Cancer Research Group website
GradeECOG Performance Status
0Fully active, able to carry on all pre-disease performance without any restriction
1Restricted in the physically strenuous activity but ambulatory and able to carry out work of the light or sedentary nature, e.g., light house work, office work
2Ambulatory and capable of all selfcare but not able to carry out any work activities; up and about more than 50% of waking hours
3Capable of only limited selfcare; confined to bed or chair more than 50% of the waking hours
4Completely disabled; cannot carry on any selfcare; totally confined to the bed or chair


- Advertisement -


  1. Hey there. I found your blog via Google at the same time as looking for a related matter, your site got here up. It appears great. I have bookmarked it in my google bookmarks to come back then.


Please enter your comment!
Please enter your name here

three × one =

Most Popular

Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia

April 21, 2021: A brand new oral treatment for an incurable blood cancer has been recommended for NHS use by NICE.

GW Pharma receives EU approval for EPIDYOLEX® for treatment of seizures

April 20, 2021: "GW Pharmaceuticals, a world leader in discovering, developing and delivering regulatory approved cannabis-based medicinesannounces that the European Commission has...

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

April 16, 2021: "Amgen announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of...

JCVI issues new advice on COVID-19 vaccination for pregnant women

April 16, 2021: There have been no specific safety concerns identified with any brand of coronavirus (COVID-19) vaccines in relation to pregnancy.